放射藥物新境界

Recent Advances in Radiopharmaceuticals: State of the Art

王勝濤(Theodore S. T. Wang)

《化學》 50卷4期 (1992/12) Pp. 434-439

https://doi.org/10.6623/chem.1992048

摘要

美國食品藥物管理局在最近兩年之間批准了數種核醫新藥，I-123 SPECTAMINE、Tc-99m EXAMETAZINE(腦)、Tc-99m SESTAMIBl、Tc-99m TEBOROXIME、Rb-82發生器(心)、Tc-99m MERTlATIDE(腎)、Tc-99m ULTRA TAG(紅血球)和代替心肌缺血運動試驗的DIPYRlDAMOLE等等顯明的大大提昇了臨床核醫診斷的範圍、技術和水準。另外目前正在進行臨床試驗的Tc-99m ECD(腦)、Tc-99m或In-111標記單株球蛋白抗體(血拴症)、腫瘤抗體(癌症)和受體(腦)等等新型核醫新藥預期不久將來會使人體的器官功能生化機轉，病理變化藉這些藥物使核醫造影診斷技術走入廣闊新的境界。

並列摘要

Over the last two years, several new diagnostic radiopharmaceuticals have been approved by the FDA of the United States of America. Two agents are used in cerebral perfusion imaging (1-123-Spectarnine, and Tc-99m Exametazine), three are used in myocardial perfusin imaging (Tc-99m Sestamibi, Tc-99m Teboroxime, and Rb-82 generator), (in addition to the new use of the pharmacological stress agent Dipyridamole, USP), one agent is used for in vitro Tc-99m-red blood cell labeling (Ultr Tag), and one is used for renal function and perfusion imaging (Tc-99m Mertiatide), Furthermore, there are many new, exciting therapeutic radiopharmaceuticals for palliation of bone pain, and labeled monoclonal antibodies for tumor therapy, which are currently in clinical IND studies in many medical centers in the USA These recent achievements in the research and development of radiopharmaceuticals have demonstrated that the technology of nuclear medicine has advanced into a new higher level of clinical diagnosis and therapy.